Leerink Partnrs Forecasts Pyxis Oncology FY2029 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for Pyxis Oncology in a research note issued on Friday, May 16th. Leerink Partnrs analyst J. La. Rosa anticipates that the company will post earnings per share of ($0.29) for the year. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.04) per share.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.06).

A number of other research firms have also commented on PYXS. HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Pyxis Oncology in a research note on Monday, May 19th. Royal Bank of Canada reiterated an "outperform" rating and issued a $8.00 price objective on shares of Pyxis Oncology in a research note on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.

Pyxis Oncology Stock Performance

Shares of Pyxis Oncology stock traded up $0.03 during trading on Monday, reaching $1.23. The company's stock had a trading volume of 471,961 shares, compared to its average volume of 741,968. The business's fifty day moving average price is $1.06 and its 200-day moving average price is $1.54. The firm has a market cap of $76.20 million, a price-to-earnings ratio of -1.19 and a beta of 1.15. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.39.

Institutional Trading of Pyxis Oncology

A number of institutional investors and hedge funds have recently modified their holdings of PYXS. Millennium Management LLC raised its position in Pyxis Oncology by 53.8% in the fourth quarter. Millennium Management LLC now owns 2,980,906 shares of the company's stock worth $4,650,000 after purchasing an additional 1,043,228 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Pyxis Oncology by 57.2% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company's stock valued at $939,000 after purchasing an additional 219,100 shares during the period. 683 Capital Management LLC raised its holdings in shares of Pyxis Oncology by 32.5% in the 1st quarter. 683 Capital Management LLC now owns 550,000 shares of the company's stock worth $539,000 after buying an additional 135,000 shares in the last quarter. Pier 88 Investment Partners LLC raised its holdings in shares of Pyxis Oncology by 296.6% in the 1st quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company's stock worth $383,000 after buying an additional 292,370 shares in the last quarter. Finally, Ridgeback Capital Investments L.P. bought a new position in shares of Pyxis Oncology during the 4th quarter worth approximately $560,000. 39.09% of the stock is currently owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.